The frequency of heterozygous ClinVar pathogenic BRCA2 GVs in unselected adult glioma patients ranged from 3/764 (0.4%) [32] to 3/152 (2%) [51], compared to 5/206 (2.4%) glioma patients with presumed tumor predisposition analyzed here. This evidence concerns the gene BRCA2 and central nervous system cancer.